15-strain live biotherapeutic product or same donor fecal microbiota transplant for recurrent Clostridioides difficile infection: a randomized phase 1b trial
Lukas Bethlehem / nature - Nature Medicine, Published online: 02 June 2026; doi:10.1038/s41591-026-04442-2A randomized, single-blind, parallel-group, phase 1b clinical trial compared fecal microbiota transplant or a 15-strain live biotherapeutic product (MTC01) derived from the sam…
AI Summary: A randomized phase 1b trial compared a defined 15‑strain live biotherapeutic product with traditional donor fecal microbiota transplant for recurrent Clostridioides difficile infection and found comparable safety and efficacy. The result supports a manufactured, standardized microbiome therapy as a realistic alternative to donor stool, simplifying logistics and regulation — and making “poop pills” slightly less artisanal.
Related Stories
One hepatitis B drug shows early functional cures in trial / 7 days
Antiviral ensitrelvir dramatically cuts household COVID transmission risk / 21 days
Favipiravir shows promise in Lassa fever Phase 2 trial / 21 days
Moderna launches mRNA bird‑flu vaccine trial as preparedness ramps up / 6 wks
FDA clears AstraZeneca’s new blood-pressure drug baxdrostat / 18 days
Gene therapy pioneers win Breakthrough Prize for CRISPR sickle‑cell work / 6 wks
First‑in‑human CRISPR/Cas12a sickle cell therapy treated; gene editing shows promise / 2 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Telemedicine, Cybersecurity, Mergers and Acquisitions, Hearing Loss and look for the RSS link.
StackHealth Time Machine